Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Exelixis Reports Positive Data From Cabozantinib Study In Renal Cell Carcinoma - NASDAQ |
 |
 |
|
NASDAQ (RTTNews.com) - Biotechnology company Exelixis, Inc. (EXEL), revealed positive updated interim data from an ongoing phase 1b trial of cabozantinib in patients with metastatic refractory renal cell carcinoma. The study endpoints included safety, |
